Evidence map›Paper›PMID 28116747›Full record

SynthesisThe Cochrane database of systematic reviews2017

Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.

Julia Ae Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood-Baker

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Romanian clinical guideline for diagnosis and treatment of COPD.The Journal of international medical research · 2020
    Guideline
  2. Pooled it
  3. Guideline
  4. Review
  5. Review
  6. Article
  7. COPD: comparative study of vaccinated and unvaccinated patients for pneumococcal disease.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Julia Ae WaltersSchool of Medicine, University of Tasmania, MSP, 17 Liverpool Street, PO Box 23, Hobart, Tasmania, Australia, 7001.
Joanne Ngie Qing TangSchool of Medicine, University of Tasmania, Hobart, Australia.
Phillippa PooleDepartment of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand.
Richard Wood-BakerSchool of Medicine, University of Tasmania, Hobart, Australia.
University of Tasmania · AUAlfred Health · AUUniversity of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.

objectivesTo determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD. SEARCH

methodsWe searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016. SELECTION CRITERIA: We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodological procedures. For meta-analyses, we subgrouped studies by vaccine type. MAIN

resultsFor this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV AUTHORS'

conclusionsInjectable polyvalent pneumococcal vaccination provides significant protection against community-acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate-quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.

Indexed as

AgedCause of DeathCommunity-Acquired InfectionsFemaleHumansMaleMiddle AgedPneumococcal InfectionsPneumococcal VaccinesPneumonia, PneumococcalPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicPneumococcal Vaccines

Identifiers

PMID28116747
PMCPMC6422320
OpenAlexW2580223878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.